Tag: pain

Demand for Compounding Pharmacies in USA to Reach USD 12.79 Billion by 2036 Amid Growing Need for Personalized Therapies and Specialized Medication Solutions

NEWARK, Del., June 2, 2026 /PRNewswire/ -- The Demand for Compounding Pharmacies in USA is projected to grow from USD 6.04 billion in 2026 to...

Recess Expands Kids’ Activities Marketplace to Dallas and Houston, Backed by More Than $4M in Venture Funding

The fast-growing startup partners with schools and leading kids' activity brands to help families book trusted camps, classes, and after-school programs. DALLAS and...

Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy

MEQUON, Wis., June 2, 2026 /PRNewswire/ -- Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the "Company") today announced that the Board of Directors...

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the...

CNI (Hong Kong) Yuanqizhi International Limited Launches Father’s Day Family Wellness Package Combining In-Home Pain Management and Nutritional Solutions

CNI (Hong Kong) Yuanqizhi International Limited launches its Father's Day Family Wellness Package, blending in-home pain management and nutrition

Reshaping PV Value: Sungrow Renewables Launches Smart Module in a Landmark Industry Debut

SHANGHAI, June 2, 2026 /PRNewswire/ -- On June 1, Sungrow Renewables held its 2026 Intelligent Technology Conference in Shanghai. Sungrow Renewables unveiled its new iBuilding...

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ^®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada¹ and complements the adolescent label extension received in Europe in April 2025².

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years

BestQool Announces Summer Promotion and Fall Refresh with New Logo and BQ60Pro Preview

Summer Appreciation Sales Offers 12% Off All Products NEW YORK, Aug. 15, 2025 /PRNewswire/ -- BestQool , a pioneer manufacturer of home-use red light therapy...

Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

– Live video webcast on Thursday, August 21^st at 2:20 PM ET

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...

Young Mother’s Battle with Arthritis Highlights Need for Timely Access to Modern Medications in BC

VANCOUVER, BC, Aug. 14, 2025 /CNW/ - Eileen Davidson, a Burnaby mother and advocate, is calling on the BC government to modernize its approach to...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsPain

Verato Named 2026 Healthcare & Life Sciences Snowflake Product Partner of the Year

Mayo Clinic and Microsoft collaborate to develop a frontier AI model for healthcare

Immuta Launches New Agentic Data Access Capabilities on Snowflake AI Data Cloud

Tag: pain

Demand for Compounding Pharmacies in USA to Reach USD 12.79 Billion by 2036 Amid Growing Need for Personalized Therapies and Specialized Medication Solutions

Recess Expands Kids’ Activities Marketplace to Dallas and Houston, Backed by More Than $4M in Venture Funding

Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

CNI (Hong Kong) Yuanqizhi International Limited Launches Father’s Day Family Wellness Package Combining In-Home Pain Management and Nutritional Solutions

Reshaping PV Value: Sungrow Renewables Launches Smart Module in a Landmark Industry Debut

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

BestQool Announces Summer Promotion and Fall Refresh with New Logo and BQ60Pro Preview

Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Young Mother’s Battle with Arthritis Highlights Need for Timely Access to Modern Medications in BC

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us